A shareholder filed a securities suit against Chemours in Delaware federal court on March 21, weeks after the company announced it was placing three members of its senior management team on leave for suspected tampering with financial reports.
Bernstein Litowitz Berger & Grossman and Kessler Topaz Meltzer & Check are representing the plaintiff in the case, which brings Exchange Act claims against Chemours, president and CEO Mark Newman, senior vice president and CFO Jonathan Lock, controller and principal accounting officer Camela Wisel and former senior vice president and CFO Sameer Ralhan.
